DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

Information source: Astellas Pharma Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pharmacokinetics of Solifenacin Succinate; Healthy Volunteers

Intervention: Solifenacin Succinate Formulation A (Drug); Solifenacin Succinate Formulation B (Drug); Solifenacin Succinate (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Astellas Pharma Inc

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Astellas Pharma Global Development


A study in healthy volunteers comparing two different liquid formulations of solifenacin with each other and with the tablet formulation.

Clinical Details

Official title: A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation B) Versus Solifenacin Liquid Suspension 10 mg (Formulation A) and to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation A and B) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet in Healthy Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Pharmacokinetic assessment of AUC and maximum concentration (Cmax) through the analysis of blood samples

Detailed description: Subjects will be randomized to one of six treatment sequences. The treatments will be separated by a minimum of 13 days between dosing. Study drug will be administered after an overnight fast, and food will be restricted for an additional four hours after dosing. Except for the water provided with dosing, water will be restricted only during the hour before and the hour after dosing. Subjects will stay at the study site for the first three days of each treatment period. Subjects will return to the study center each morning at the same time of the day for Days 4 through 11 of each study period for the pharmacokinetic blood draw and vital signs. Subjects will be in the study for at least 40 days.


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- Subject weighs at least 45 kg, and has a body mass index of 18 to 32 kg/m2

- Subject has a normal 12-lead electrocardiogram (ECG)

- Subject, if female, must be at least 2 years postmenopausal, surgically sterile, or

practicing effective birth control, and is not pregnant or lactating

- Subject has good venous access

Exclusion Criteria:

- The subject has a history of any clinically significant disease or malignancy with

the exception of non-melanoma skin cancer

- The subject has a history of or currently has evidence of urinary retention, gastric

retention, or uncontrolled narrow-angle-glaucoma

- The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac

arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes)

- The subject has a known hypersensitivity to VESIcare® or any of the excipients in the

formulations, or the subject has a history of severe allergic or anaphylactic reactions

- The subject has a history of consuming more than 15 units of alcoholic beverages per

week, or has a history of alcoholism or substance abuse within the past two years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits)

- The subject has used tobacco containing products or nicotine containing products

within past six months

- The subject has a supine mean systolic blood pressure < 90 or > 160 mmHg and a mean

diastolic blood pressure < 50 or > 90 mmHg, or pulse rate < 40 or >100 beats per minute

- The subject is known to be positive for human immunodeficiency virus antibody

- The subject has a positive test for hepatitis C antibody or hepatitis B antigen

- The subject's laboratory test results are outside the normal limits and considered

to be clinically significant

- The subject has had treatment with prescription or non-prescription drugs, including

complementary and alternative medicines or over-the-counter medications, with the exception of hormonal contraceptives, hormone replacement therapy, and occasional use of acetaminophen within 14 days prior to inclusion into the study

- The subject anticipates an inability to abstain from alcohol or caffeine use

throughout the duration of the study or from grapefruit, Seville oranges, star fruit, or any products containing these items from throughout the duration of the study

- The subject has received an experimental agent within past 30 days or ten half-lives,

whichever is longer

- The subject has had any significant blood loss

- The subject has any clinically significant history of gastrointestinal symptoms such

as nausea, abdominal discomfort or upset, or heartburn in the four weeks prior to clinic admission, or a history of any gastrointestinal surgery except for appendectomy or cholecystectomy

Locations and Contacts

Spaulding Clinical Research, West Bend, Wisconsin 53095, United States
Additional Information

Starting date: May 2011
Last updated: August 23, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017